Linda Cerbone

1.2k total citations
34 papers, 480 citations indexed

About

Linda Cerbone is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Linda Cerbone has authored 34 papers receiving a total of 480 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 13 papers in Surgery. Recurrent topics in Linda Cerbone's work include Renal cell carcinoma treatment (11 papers), Bladder and Urothelial Cancer Treatments (10 papers) and Urinary and Genital Oncology Studies (6 papers). Linda Cerbone is often cited by papers focused on Renal cell carcinoma treatment (11 papers), Bladder and Urothelial Cancer Treatments (10 papers) and Urinary and Genital Oncology Studies (6 papers). Linda Cerbone collaborates with scholars based in Italy, United States and United Kingdom. Linda Cerbone's co-authors include Cora N. Sternberg, K.N. Chi, Mohammad Hirmand, Karim Fizazi, Andrea Zivi, David Forer, Howard I. Scher, Johann S. de Bono, Fabio Calabrò and Federica Recine and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Linda Cerbone

31 papers receiving 472 citations

Peers

Linda Cerbone
Urbano Anido Spain
Zhaofei Pang China
Francesca Barbisan Italy
Hae Su Kim South Korea
María José Méndez-Vidal Spain
Valentina Tateo Italy
Yasuhiro Arakawa Japan
Yungpo Bernard Su United States
Elisa Bacillo Italy
Ana Castro Portugal
Urbano Anido Spain
Linda Cerbone
Citations per year, relative to Linda Cerbone Linda Cerbone (= 1×) peers Urbano Anido

Countries citing papers authored by Linda Cerbone

Since Specialization
Citations

This map shows the geographic impact of Linda Cerbone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linda Cerbone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linda Cerbone more than expected).

Fields of papers citing papers by Linda Cerbone

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linda Cerbone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linda Cerbone. The network helps show where Linda Cerbone may publish in the future.

Co-authorship network of co-authors of Linda Cerbone

This figure shows the co-authorship network connecting the top 25 collaborators of Linda Cerbone. A scholar is included among the top collaborators of Linda Cerbone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linda Cerbone. Linda Cerbone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cerbone, Linda, Sara Delfanti, Paola Barbieri, et al.. (2024). Rucaparib in refractory pleural mesothelioma harboring somatic pathogenic BRCA1 and BRCA2 mutation. A report of two cases. PubMed. 14(1). 2424133–2424133. 1 indexed citations
2.
Guida, Annalisa, Alessio Gili, Claudia Mosillo, et al.. (2024). Efficacy and Safety of Pembrolizumab plus Axitinib combination for Metastatic Renal Cell Carcinoma in a Real-World Scenario: Data From the Prospective ProPAXI Study. Clinical Genitourinary Cancer. 22(6). 102225–102225.
3.
Santoni, Matteo, Hideki Takeshita, Francesco Massari, et al.. (2024). Pembrolizumab plus enfortumab vedotin in urothelial cancer. Nature Reviews Urology. 21(7). 387–388. 3 indexed citations
4.
Baciarello, Giulia, et al.. (2023). Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma. Cancer Drug Resistance. 6(3). 517–46. 10 indexed citations
5.
Sternberg, Cora N., Nara Shin, Fabio Calabrò, et al.. (2022). Case report: Metastatic urothelial cancer with an exceptional response to immunotherapy and comprehensive understanding of the tumor and the tumor microenvironment. Frontiers in Oncology. 12. 1006017–1006017. 2 indexed citations
6.
Trenta, Patrizia, Fabio Calabrò, Linda Cerbone, & Cora N. Sternberg. (2016). Chemotherapy for Muscle-Invasive Bladder Cancer. Current Treatment Options in Oncology. 17(1). 6–6. 21 indexed citations
7.
Cerbone, Linda, Cora N. Sternberg, Lisa Sengeløv, et al.. (2015). Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061. Oncology. 90(1). 21–28. 25 indexed citations
8.
Vincenzi, Bruno, Linda Cerbone, Mariella Spalato Ceruso, et al.. (2015). Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study. Scientific Reports. 5(1). 12077–12077. 2 indexed citations
9.
Bellmunt, Joaquim, Francesc Pons, André P. Fay, et al.. (2014). Sequential Targeted Therapy After Pazopanib Therapy in Patients With Metastatic Renal Cell Cancer: Efficacy and Toxicity. Clinical Genitourinary Cancer. 12(4). 262–269. 10 indexed citations
10.
Milowsky, Matthew I., Christian Dittrich, Ignacio Durán, et al.. (2014). Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. European Journal of Cancer. 50(18). 3145–3152. 82 indexed citations
11.
Sternberg, Cora N., Johann S. de Bono, K.N. Chi, et al.. (2014). Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Annals of Oncology. 25(2). 429–434. 101 indexed citations
12.
Cerbone, Linda, Rita Van Ginderdeuren, Joost van den Oord, et al.. (2014). Clinical Presentation, Pathological Features and Natural Course of Metastatic Uveal Melanoma, an Orphan and Commonly Fatal Disease. Oncology. 86(3). 185–189. 20 indexed citations
13.
Sternberg, Cora N., Iwona Skoneczna, Daniel Castellano, et al.. (2013). Larotaxel with Cisplatin in the First-Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer: A Randomized, Active-Controlled, Phase III Trial (CILAB). Oncology. 85(4). 208–215. 30 indexed citations
14.
Zivi, Andrea, Linda Cerbone, Federica Recine, & Cora N. Sternberg. (2012). Safety and tolerability of pazopanib in the treatment of renal cell carcinoma. Expert Opinion on Drug Safety. 11(5). 851–859. 27 indexed citations
15.
16.
Paola, Eugenio Donato Di, S. Alonso, Rosa Giuliani, et al.. (2012). An open-label, dose-finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors. SHILAP Revista de lepidopterología. 2. 175–175. 2 indexed citations
17.
Russo, Giuseppe Lo, Fabio Accarpio, Gian Paolo Spinelli, et al.. (2012). Subcutaneous metastases from colon cancer: a case report. Journal of Medical Case Reports. 6(1). 212–212. 4 indexed citations
18.
Mancuso, Andrea, Eugenio Donato Di Paola, Alvaro Leone, et al.. (2011). Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti‐angiogenic treatment. British Journal of Urology. 109(2). 200–206. 22 indexed citations
19.
Mancuso, Andrea, et al.. (2010). Patient With Colorectal Cancer With Heterogeneous KRAS Molecular Status Responding to Cetuximab-Based Chemotherapy. Journal of Clinical Oncology. 28(36). e756–e758. 13 indexed citations
20.
Cerbone, Linda, Rita Van Ginderdeuren, Joost van den Oord, et al.. (2009). 9326 Clinical presentation, pathological features and natural course of metastatic uveal melanoma (MUM) as an orphan and commonly fatal disease. European Journal of Cancer Supplements. 7(2). 585–585. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Urbano Anido Breakdown of academic impact, for papers by Zhaofei Pang Breakdown of academic impact, for papers by Francesca Barbisan Breakdown of academic impact, for papers by Hae Su Kim Breakdown of academic impact, for papers by María José Méndez-Vidal Breakdown of academic impact, for papers by Valentina Tateo Breakdown of academic impact, for papers by Yasuhiro Arakawa Breakdown of academic impact, for papers by Yungpo Bernard Su Breakdown of academic impact, for papers by Elisa Bacillo Breakdown of academic impact, for papers by Ana Castro
Rankless by CCL
2026